Abstract
EE536 Cost-Effectiveness of Axicabtagene Ciloleucel (axi-cel) Vs Standard of Care for Adult Patients with Relapsed or Refractory Follicular Lymphoma as 4TH or Later Line Treatment in Sweden
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
